Head-to-head
PT-141 vs Kisspeptin-10
A field-by-field comparison of PT-141 and Kisspeptin-10 drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as sexual health compounds, so the useful question is how they differ within that category.
PT-141 vs Kisspeptin-10 at a glance
| Attribute | PT-141 | Kisspeptin-10 |
|---|---|---|
| Category | Sexual health | Sexual health |
| Evidence grade | Strong | Emerging |
| Also known as | Bremelanotide, Vyleesi | Metastin fragment 45-54 |
| Chain | Cyclic heptapeptide, Melanotan II metabolite | Decapeptide fragment of kisspeptin |
| Mechanism | Selectively activates MC4R in the hypothalamus, increasing dopaminergic signalling in the medial preoptic area — driving desire itself rather than blood flow, unlike PDE5 inhibitors. | Binds KISS1R on GnRH neurons, stimulating pulsatile GnRH release and downstream LH and FSH secretion — the master switch of the hypothalamic–pituitary–gonadal axis. |
| Reported benefits | Increased sexual desire in both sexes · Works independently of vascular function · Effective as an on-demand dose | Increased LH and testosterone signalling · Enhanced limbic response to sexual stimuli in imaging studies · Fertility applications under investigation |
| Reported side effects | Nausea and vomiting · Flushing · Headache · Transient blood-pressure increase | Limited safety data · Headache · Possible hormonal disruption with chronic use |
| Half-life | About 2.7 hours | Under 30 minutes |
| Administration | Subcutaneous auto-injector, 45 minutes before activity | Subcutaneous injection |
| Dosing overview | 1.75 mg as needed, maximum one dose per 24 hours | Research doses vary; community use is typically low-microgram and infrequent |
| Storage | Room temperature for the approved auto-injector | Refrigerated after reconstitution |
| Legal status | FDA-approved (Vyleesi) for premenopausal HSDD; other uses are off-label. | Research chemical, not approved for human use. |
Key differences between PT-141 and Kisspeptin-10
Both are sexual health compounds
PT-141 and Kisspeptin-10 are both indexed under sexual health, so they compete for the same use case rather than complementing each other. PT-141: "An FDA-approved melanocortin agonist for hypoactive sexual desire disorder that works through the central nervous system rather than the vascular system." Kisspeptin-10: "An upstream regulator of the reproductive axis studied for libido, fertility and hormone signalling."
Mechanism of action
PT-141: Selectively activates MC4R in the hypothalamus, increasing dopaminergic signalling in the medial preoptic area — driving desire itself rather than blood flow, unlike PDE5 inhibitors. Kisspeptin-10: Binds KISS1R on GnRH neurons, stimulating pulsatile GnRH release and downstream LH and FSH secretion — the master switch of the hypothalamic–pituitary–gonadal axis.
Evidence quality is not equal
PT-141 carries a Strong evidence grade and Kisspeptin-10 a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — PT-141 has the better-documented record of the two, and claims made about Kisspeptin-10 rest on thinner human evidence.
Half-life and dosing frequency
PT-141 is listed at about 2.7 hours; Kisspeptin-10 at under 30 minutes. That difference is what drives the reported schedules: 1.75 mg as needed, maximum one dose per 24 hours versus Research doses vary; community use is typically low-microgram and infrequent
Route of administration
PT-141 is administered by subcutaneous auto-injector, 45 minutes before activity. Kisspeptin-10 is administered by subcutaneous injection.
Legal and regulatory status differs
PT-141: FDA-approved (Vyleesi) for premenopausal HSDD; other uses are off-label. Kisspeptin-10: Research chemical, not approved for human use. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
PT-141 is stored room temperature for the approved auto-injector. Kisspeptin-10 is stored refrigerated after reconstitution.
What PT-141 and Kisspeptin-10 have in common
- Category: both listed as Sexual health
Both profiles list the same reported side effects: headache.
Each compound in brief
PT-141
Sexual health · Strong evidence
An FDA-approved melanocortin agonist for hypoactive sexual desire disorder that works through the central nervous system rather than the vascular system.
Considerations: Raises blood pressure transiently — avoid with uncontrolled hypertension · Nausea is common at higher doses · Label limits use to eight doses per month
Kisspeptin-10
Sexual health · Emerging evidence
An upstream regulator of the reproductive axis studied for libido, fertility and hormone signalling.
Considerations: Continuous exposure can desensitise the receptor — pulsatile use matters · Human data comes from small imaging and endocrine studies · Not a testosterone replacement
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.